SUMMARY

• The company cannot recommend any practices, procedures or usage that deviate from the approved labeling.
• A case report of TREMFYA use in a patient with psoriasis and coexistent systemic lupus erythematous (SLE) and acquired hemophilia A (AHA) is described.¹

Case Report

Trovato et al (2021)¹ described the case of a 62-year-old female with psoriasis and co-existent SLE and AHA treated with TREMFYA.

• The patient presented to the clinic in 2020 with erythematous-desquamative plaques of histologically proven psoriasis with a psoriasis area and severity index (PASI) score of 11.4 and dermatology life quality index (DLQI) score of 18.
• The patient’s past medical history included a diagnosis of SLE diagnosed at age 22 and AHA diagnosed in 2018.
• SLE was being treated with 4 mg/day of methylprednisolone with good disease control and AHA was treated and resolved with high dose methylprednisolone gradually tapered over 3 months.
• Patient’s psoriasis developed 4 years prior to visit and was controlled with calcipotriol and betamethasone ointment for 3 years. Due to disease state severity, dimethylfumarate was prescribed and interrupted after 3 months for intolerance (diarrhea).
• Following discussions between the rheumatologist and hematologist, treatment with TREMFYA was initiated (100 mg at weeks 0 and 4, then every 8 weeks thereafter) along with methylprednisolone (4 mg/day).
• After 2 months of treatment with TREMFYA, the patient achieved a 90% improvement in PASI response and the maintained response at the 6-month follow-up with no relapse of SLE or AHA and no reported side effects.

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 10 May 2024.